Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F-C Bidard

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Critical Reviews in Oncology/Hematology|June 18, 2011
Disseminated and circulating tumor cells in gastrointestinal oncologyF C Bidard, F R Ferrand, F Huguet, et al.
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.
ESMO Open|September 4, 2024
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?C Valenza, D Trapani, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept studyL Cabel, F Riva, V Servois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trialJ-Y Pierga, F-C Bidard, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2015
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancerF-C Bidard, C K Y Ng, P Cottu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principleL De Mattos-Arruda, B Weigelt, J Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)H Bonnefoi, T Grellety, O Tredan, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Critical Reviews in Oncology/Hematology|June 18, 2011
Disseminated and circulating tumor cells in gastrointestinal oncologyF C Bidard, F R Ferrand, F Huguet, et al.
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.
ESMO Open|September 4, 2024
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?C Valenza, D Trapani, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept studyL Cabel, F Riva, V Servois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trialJ-Y Pierga, F-C Bidard, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2015
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancerF-C Bidard, C K Y Ng, P Cottu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principleL De Mattos-Arruda, B Weigelt, J Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)H Bonnefoi, T Grellety, O Tredan, et al.
Pageof 5